RSS Feeds
The Human T-cell Leukemia/Lymphoma Virus, Lymphoma, Lytic Bone Lesions, and Hypercalcemia
- DOUGLAS W. BLAYNEY, M.D.;
- ELAINE S. JAFFE, M.D.;
- RICHARD I. FISHER, M.D.;
- GERALDINE P. SCHECHTER, M.D.;
- JEFFREY COSSMAN, M.D.;
- MARJORIE ROBERT-GUROFF, Ph.D.;
- V. S. KALYANARAMAN, Ph.D.;
- WILLIAM A. BLATTNER, M.D.; and
- ROBERT C. GALLO, M.D.
Abstract
The human T-cell lymphoma (HTL) virus is a type C RNA tumor virus isolated from patients with malignancies of mature T cells. We report three patients with peripheral T-cell lymphoma, hypercalcemia, and antibodies to HTL virus. One patient presented with idiopathic hypercalcemia of 6 months' duration, two with striking lytic bone lesions, and two with circulating malignant lymphocytes. Malignant cells from all patients had surface markers characteristic of thymic-derived lymphocytes (T cells), and all patients had natural serum antibodies to disrupted HTL virus and to one or both viral structural proteins p19 and p24. Patients with adult peripheral T-cell lymphomas, particularly those that present with hypercalcemia and lytic bone lesions, may have antibodies to the type C RNA human tumor virus, HTL virus.
Article and Author Information
-
▸From the Environmental Epidemiology Branch, Laboratory of Pathology, Medicine Branch, and the Laboratory of Tumor Cell Biology, National Cancer Institute, Bethesda, Maryland; Hematology Section, Veteran's Administration Medical Center, and Department of Medicine, George Washington University, Washington, D.C.; and the Department of Cell Biology, Litton Bionetics Inc., Kensington, Maryland.
-
▸Requests for reprints should be addressed to Douglas W. Blayney, M.D.; Landow Building, Room 4C18, National Institutes of Health; Bethesda, MD 20205.
Related Clinical Content
